Finch Therapeutics Q2 net loss $15.2M; cash $168.1M; Takeda accelerates UC program

Finch Therapeutics Group, Inc.

Net loss $15.2M vs $8.3M YoY; R&D expense $14.0M, G&A $5.9M.
Cash and equivalents $168.1M at June 30, 2021, expected to fund operations into mid-2023.
Takeda elected to accelerate leadership of FIN-524/TAK-524 ulcerative colitis program.
CP101 open-label PRISM-EXT topline data from >130 patients expected H2 2021.
Topline data from FIN-211 in ASD and CP101 in chronic HBV expected H2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.